youtube_live
Q3 2026 earnings • released • EPS beat +16.23% • Revenue beat +6.36%
See resultschevron_right
GILD:NASDAQ
Gilead Sciences, Inc
$170.33
arrow_downward
-0.21%(-0.35) 1D
$170.86
arrow_upward
+0.31% (+0.53)bedtimeAfter hours
Closed: Nov 2, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD...
Open
$169.85
High
$172.61
Low
$166.38
Mkt. cap
211.20B
Avg. vol.
5.93M
Volume
8.88M
Dividend
1.93%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$175.65
52-wk low
$116.88
EPS
-$3.15
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
Open
$169.85
High
$172.61
Low
$166.38
Mkt. cap
211.20B
Avg. vol.
5.93M
Volume
8.88M
Dividend
1.93%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$175.65
52-wk low
$116.88
EPS
-$3.15
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
News stories
From web sources and news partners
Investing.com
·
2 hours ago
Gilead Sciences CEO Daniel O’Day sells $5.3M in shares
Benzinga
·
11 hours ago
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Investing.com
·
14 hours ago
Bernstein raises Gilead Sciences stock price target on strong growth
GuruFocus
·
18 hours ago
Gilead Sciences (GILD) Maintains Quarterly Dividend Amid Mixed V
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com
Analyst ratings
Based on 22 analysts giving stock ratings to GILD in the past 3 months
Strong buy
Buy
17
Hold
5
Sell
0
12-month forecast
Based on 22 Wall Street analysts offering 12 month price targets for GILD in the last 3 months.
Highest
Current $170.33
$200.00 (+17.42%)
Average
$172.57 (+1.32%)
Lowest
$131.00 (-23.09%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Daina Graybosch Leerink Partners | Hold | Maintained | $145.00 | -14.9% | 11/02/2026 |
Evan Seigerman BMO Capital | Buy | Maintained | $184.00 | +8% | 11/02/2026 |
Umer Raffat Evercore ISI | Buy | Maintained | - | - | 10/30/2026 |
Chris Schott J.P. Morgan | Buy | Reiterated | $190.00 | +11.5% | 10/30/2026 |
Gregory Renza Truist Financial | Buy | Maintained | $181.00 | +6.3% | 10/30/2026 |
Louise Chen Scotiabank | Buy | Maintained | $200.00 | +17.4% | 10/30/2026 |
Terence Flynn Morgan Stanley | Buy | Reiterated | $183.00 | +7.4% | 10/30/2026 |
Tyler Van Buren TD Cowen | Buy | Maintained | $175.00 | +2.7% | 10/30/2026 |
Salveen Richter Goldman Sachs | Hold | Maintained | $155.00 | -9% | 10/29/2026 |
Michael Yee UBS | Buy | Reiterated | $195.00 | +14.5% | 10/30/2026 |
Carter Gould Cantor Fitzgerald | Buy | Maintained | $175.00 | +2.7% | 10/29/2026 |
Brian Abrahams RBC Capital | Hold | Maintained | $131.00 | -23.1% | 10/29/2026 |
Joseph Stringer Needham | Buy | Maintained | $200.00 | +17.4% | 10/30/2026 |
Geoff Meacham Citi | Buy | Maintained | $188.00 | +10.4% | 10/30/2026 |
Mohit Bansal Wells Fargo | Buy | Reiterated | $190.00 | +11.5% | 10/30/2026 |
Emily Field Barclays | Hold | Maintained | $145.00 | -14.9% | 10/28/2026 |
Brian Skorney Robert W. Baird | Hold | Maintained | $145.00 | -14.9% | 10/27/2026 |
Courtney Breen Bernstein | Buy | Maintained | $160.00 | -6.1% | 10/25/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Reiterated | $172.00 | +1% | 10/20/2026 |
Morten Herholdt HSBC | Buy | Maintained | $175.00 | +2.7% | 09/10/2026 |
Salim Syed Mizuho Securities | Buy | Maintained | $170.00 | -0.2% | 08/31/2026 |
Michael Okunewitch Maxim Group | Buy | Reiterated | $165.00 | -3.1% | 08/06/2026 |
Akash Tewari Jefferies | Buy | Maintained | $180.00 | +5.7% | 05/22/2026 |
Unknown Analyst Argus Research | Buy | Reiterated | $165.00 | -3.1% | 05/15/2026 |
Matthew Biegler Oppenheimer | Buy | Reiterated | $165.00 | -3.1% | 05/13/2026 |
Last report
Oct 29, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$2.55 / $2.19
+16.23%beat
arrow_upward
Revenue / Est. (USD)
8.30B / 7.80B
+6.36%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 7.92B | 6.96B | 7.80B | 8.30B |
Cost of goods sold | 1.62B | 1.44B | 1.58B | 1.57B |
Cost of revenue | 1.62B | 1.44B | 1.58B | 1.57B |
Research and development expenses | 1.57B | 1.36B | 1.69B | 1.60B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.78B | 1.43B | 1.91B | 1.61B |
Operating expense | 3.34B | 2.78B | 3.60B | 3.21B |
Total operating expenses | 4.96B | 4.23B | 5.18B | 4.78B |
Operating income | 2.96B | 2.73B | 2.63B | 3.52B |
Other non operating income | 3.00M | -8.00M | - | -7.00M |
EBT including unusual items | 2.08B | 2.58B | -10.25B | 3.06B |
EBT excluding unusual items | 2.80B | 2.59B | 2.42B | 3.29B |
Income tax expense | -105.00M | 559.00M | 242.00M | 634.00M |
Effective tax rate | -5.05% | 21.67% | -2.36% | 20.70% |
Other operating expenses | - | - | - | - |
Net income | 2.18B | 2.02B | -10.50B | 2.43B |
Net profit margin | 27.55% | 29.04% | -134.51% | 29.27% |
Earnings per share | 1.86 | 2.03 | -6.75 | 2.55 |
Interest and investment income | 95.00M | 95.00M | 45.00M | 41.00M |
Interest expense | -255.00M | -240.00M | -247.00M | -269.00M |
Net interest expenses | -160.00M | -145.00M | -202.00M | -228.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 3.65B | 3.42B | 3.33B | 4.26B |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events